

Fax completed form to: 1-866-868-0858  
Questions, please call: 1-866-316-6049



## **Important Information About Prescription Drug Coverage**

---

To: \_\_\_\_\_ From: \_\_\_\_\_

Fax: \_\_\_\_\_ Pages: \_\_\_\_\_

Re: Vidaza® (Azacitidine): Prior Authorization Request Form: Please respond.

---

- Please complete the attached Vidaza® (Azacitidine) Prior Authorization Request Form
- To expedite the review process please complete all requested fields.
- Completed forms should be faxed to: 1-866-868-0858. It is not necessary to fax this cover page.

**Please note:** By signing the attached form you are certifying that the treatment requested is medically necessary. No contraindications are present and precautions have been considered. You will be supervising the patient's treatment. Supporting documentation is available in the patient's record. Signature on this form attests to the fact that the corresponding ICD-9 code has been documented in the patients chart and submitted on a CMS- 1500 form.

### Information about this drug

---

#### Vidaza®(Azacitidine)

Azacitidine and its metabolites are renally excreted and toxic reactions to the drug are increased in patients who are renally impaired. Because elderly patients are more likely to have decreased renal function, it is recommended to monitor renal function during receipt of Vidaza®.

You can make an expedited request by indicating this at the top of the attached form. If you request an expedited review, and sign the attached form, you certify that applying the 72 hour standard review time frame may seriously jeopardize the life or health of the member or the member's ability to regain maximum function.

**Information on the attached form is protected health information and subject to all privacy and security regulations under HIPAA.**

MemberHealth, LLC, PO Box 391197, Solon OH 44139-3911

Last Updated: 01/21/2008  
S5803\_07P0126\_v2 (11/2007)

# Prior Authorization Request Form

Fax completed form to 1-866-868-0858 Need help? Call 1-866-316-6049

## Patient Information

Name \_\_\_\_\_  
Member ID \_\_\_\_\_  
Medicare ID \_\_\_\_\_  
Date of birth \_\_\_\_\_ Sex: M / F  
Address \_\_\_\_\_  
City \_\_\_\_\_  
State \_\_\_\_\_ ZIP \_\_\_\_\_  
Phone \_\_\_\_\_  
Nursing home resident? YES / NO  
Home care patient? YES / NO

## Prescriber and Pharmacy Information

Name \_\_\_\_\_  
Specialty \_\_\_\_\_  
DEA \_\_\_\_\_  
NPI \_\_\_\_\_  
Address \_\_\_\_\_  
City \_\_\_\_\_  
State \_\_\_\_\_ ZIP \_\_\_\_\_  
Phone \_\_\_\_\_ Fax \_\_\_\_\_  
Pharmacy name \_\_\_\_\_  
NCPDP \_\_\_\_\_  
NPI \_\_\_\_\_  
Phone \_\_\_\_\_ Fax \_\_\_\_\_

## All items below this line are for Physician Use Only

### Information for Requested Drug

Strength: \_\_\_\_\_ Dosage form: \_\_\_\_\_ Qty per 30 days: \_\_\_\_\_ Drug is (circle one): Newly prescribed/Refill  
Directions: \_\_\_\_\_ Diagnosis: \_\_\_\_\_ ICD-9 Code: \_\_\_\_\_

Standard Reviews will be completed in under 72 hours. An expedited review is available if you certify that a standard review timeframe will seriously jeopardize the health of your patient. To request an expedited review, simply indicate this at the top of this page.

### Vidaza®(Azacitidine) Criteria

- 1 Please indicate Vidaza®'s dispensing location:  
 the pharmacy  
 the physician's office incident to a physician's visit  
 other: \_\_\_\_\_
  - 2 Please indicate the patient's diagnosis. Select or indicate the patient's diagnosis. **This question must be completed.**  
 Myelodysplastic Syndrome, Refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, chronic myelomonocytic leukemia (ICD-9: 238.72, 238.73, 238.74, 238.75)  
 Other (diagnosis and ICD-9 code): \_\_\_\_\_
  - 3 Will Vidaza® be administered in a facility where the patient can be closely monitored for an appropriate period based on health status?  
 Yes  No
  - 4 Is the prescribing physician a hematologist/oncologist or has one been consulted?  
 Yes  No
  - 5 Does the patient have any contraindications to Vidaza® (e.g., advanced malignant hepatic tumors, known hypersensitivity to azacitidine or mannitol)?  
 Yes  No
- Vidaza® should be used cautiously in patients with a serum baseline albumin less than 30 g/L, pre-existing liver disease, unexplained decreases in serum bicarbonate less than 20 mEq/L or elevations of BUN or serum creatinine.

Medical Justification: (Attach additional page if necessary): \_\_\_\_\_

Prescriber's signature: \_\_\_\_\_ Date: \_\_\_\_\_